Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6031 to 6045 of 8218 results

  1. Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification when selecting which people with CUADT would benefit from short- or long-term enteral nutrition?

    Recommendation ID NG36/4 Question Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification

  2. Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and pathological factors?

    Recommendation ID NG36/3 Question Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary

  3. Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having metastasis or a second primary cancer?

    Recommendation ID NG36/1 Question Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having

  4. Positive workplaces for social workers

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers {"@context":"http://schema

  5. Principal social workers - children

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers {"@context":"http://schema

  6. Our charter

    An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.

  7. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  8. Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars

    More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.

  9. NICE recommends new treatment option for highly active multiple sclerosis

    Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.

  10. NICE announces Professor Jonathan Benger as new Chief Executive

    NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.

  11. New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier

    More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.

  12. New sepsis guideline targets faster, tailored treatments to benefit patients

    Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.

  13. Digital platforms recommended to help people manage their asthma

    People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.

  14. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.